EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

L26/P-869 Pregnancy after breast cancer and associated maternal and neonatal outcomes: updated evidence from a systematic review and meta-analysis

B. Paans, E. Balkenende, M. Goddijn, D. Van Riet, Z. Hillebrand, M. Kurul, M. Van Wely

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.1193 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von B. Paans und 6 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study question What differences in pregnancy, maternal, and neonatal outcomes exist between women with and without a prior diagnosis of breast cancer? Summary answer Women diagnosed with breast cancer show reduced conception rates, while active attempts improved conception. Least favorable outcomes were observed in those receiving endocrine therapy. What is known already Breast cancer is the most frequently diagnosed invasive cancer among women of reproductive age. Previous cancer treatments may affect fertility and pregnancy outcomes, highlighting the need to understand potential pregnancy-related, maternal and neonatal risks in women conceiving after breast cancer. Previous studies have provided evidence on the safety of conceiving after breast cancer, while also showing increased risks of preterm birth and low birth weight. Improved insights regarding these outcomes is crucial to support evidence-based counselling and optimal pregnancy management. Earlier reviews lacked comprehensive information on breast cancer–specific factors and treatments that could have affected the reported outcomes. Study design, size, duration This study is a systematic review and meta-analysis, which provides an update on the current literature and included observational studies who compare women with a history of breast cancer to women without a prior breast cancer diagnosis (Prospero: CRD420251235696). This abstract is based on a search conducted in PubMed in September 2025. A full systematic literature search in Medline, EMBASE, CENTRAL and CINAIL was performed covering the period from January 2000 to 20 January 2026. Participants/materials, setting, methods The preliminary review included 28 studies (48,900 women with a history of breast cancer). Results were separated for pregnancy (pregnancy, live birth), maternal (hypertensive disorders, gestational diabetes, caesarean section), and neonatal (preterm birth, low birth weight, congenital malformations, NICU admission) outcomes. Risk of bias was assessed using ROBINS-E. Adjusted hazard ratios and relative risks were extracted. Meta-analyses were performed using a random effects model. Subgroup analyses were performed according to the type of cancer treatment. Main results and the role of chance The risk of bias in the included studies varied from moderate to high, primarily due to their observational design, confounding, selection bias, and heterogeneity in outcome definitions and adjustment strategies. Preliminary data estimated an overall pooled pregnancy prevalence of 13% (95% CI 0.10-0.17) among all breast cancer survivors of reproductive age. Among those who actively attempted to conceive, this ranged from 25%-73.9%. The pooled adjusted HR for pregnancy was 0.40 (95% CI 0.38-0.42) for BC survivors compared to controls. Among pregnancies that occurred, 65% resulted in live births. The pooled adjusted HR for live birth among BC survivors compared with controls was 0.42 (95% CI 0.39-0.45). Significant differences were observed for preterm birth (RRadj 1.23, 95%CI: 1.06-1.44), low birth weight (RRadj 1.35, 95%CI: 1.15-1.59) and caesarean section (RRadj 1.16, 95%CI: 1.10-1.22). We found no significant differences between breast cancer survivors and controls for preeclampsia ( RRadj = 0.88 (95% CI: 0.65-1.17), gestational diabetes (RRadj = 0.97 (95% CI: 0.72 -1.30) or congenital malformations ( RRadj = 1.22 (95%CI: 0.86-1.73). None of the included studies reported on NICU admission. Only two studies performed subgroup analyses of cancer treatments, and suggested that pregnancy rates were least favorable when endocrine therapy was administered. Limitations, reasons for caution Heterogeneity in study populations, follow-up duration, and outcome reporting methods limits comparability across studies. Data stratified by disease severity and type of cancer treatment were often unavailable, and differences in study design and adjustment methods may affect pooled estimates. The results of the current review are being updated. Wider implications of the findings These results highlight the need for personalized reproductive counseling and tailored obstetric care for breast cancer survivors, particularly for those receiving endocrine therapy. The findings also underscore the need for larger, high-quality studies to better evaluate neonatal outcomes, such as NICU admissions. Trial registration number Yes

Zitieren

APA

Paans, B., Balkenende, E., Goddijn, M., Riet, D. V., Hillebrand, Z., Kurul, M., & Wely, M. V. (2026). L26/P-869 Pregnancy after breast cancer and associated maternal and neonatal outcomes: updated evidence from a systematic review and meta-analysis. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.1193

Vancouver

Paans B, Balkenende E, Goddijn M, Riet DV, Hillebrand Z, Kurul M, et al. L26/P-869 Pregnancy after breast cancer and associated maternal and neonatal outcomes: updated evidence from a systematic review and meta-analysis. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.1193

BibTeX
@article{Paans2026,
  author = {Paans, B. and Balkenende, E. and Goddijn, M. and Riet, D. Van and Hillebrand, Z. and Kurul, M. and Wely, M. Van},
  title = {L26/P-869 Pregnancy after breast cancer and associated maternal and neonatal outcomes: updated evidence from a systematic review and meta-analysis},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.1193}
}
Kostenlos starten →